Ansimar (doxofylline) / ICE GROUP, Orient Europharma, Alitair Pharma - LARVOL DELTA

Effects of Oral Doxofylline and Procaterol on Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4 | N=20 | Completed | Sponsor: Thammasat University | Not yet recruiting ➔ Completed

Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Development of a rapid method for the simultaneous determination of aminophylline, doxofylline, bromhexine, and ambroxol by HPLC. (PubMed, Sci Prog) - " The established HPLC method is simple, reliable, and stable, allowing for the simultaneous determination of the four antitussive and expectorant drugs. APL, DXL, BXH, and AXH were stable within 48 hours when mixed with 0.9% sodium chloride and 5% glucose injections."

Journal • Respiratory Diseases

Efficacy and safety profile of doxofylline in asthma: a meta-analysis. (PubMed, J Asthma) - "Subgroup analysis results indicated that the improvement in FEV1 with doxofylline combined with budesonide was superior to that of budesonide combined with montelukast or tiotropium but inferior to that of budesonide plus formoterol combination. Doxofylline treatment significantly reduces the risk of asthma events and adverse events (AEs), demonstrating good safety and longer-term benefits."

Journal • Retrospective data • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Role of Doxofylline, Low Dose Theophylline, and Dexamethasone in Mice (BALB/C) Model of Corticosteroid Resistant Asthma: A Comparative Study. (PubMed, Ann Clin Lab Sci) - "Doxofylline and LDT were found to be effective therapeutic agents when used alone or in combination with Dexamethasone. However, randomized controlled trials are required to evaluate its further efficacy."

Clinical • Journal • Preclinical • Asthma • Immunology • Inflammation • Oncology • Pulmonary Disease • Respiratory Diseases • CXCL8 • HDAC2 • IFNG • IL10 • IL17A • IL4 • NR3C1 • TNFA

Assessment of Bitterness in Non-Charged Pharmaceuticals with a Taste Sensor: A Study on Substances with Xanthine Scaffold and Allopurinol. (PubMed, Molecules) - "In this study, the authors modified a taste sensor with 3-bromo-2,6-dihydroxybenzoic acid and used it in conjunction with sensory tests to assess the bitterness of non-charged pharmaceuticals with xanthine scaffolds (i.e., acefylline and doxofylline), as well as allopurinol, an analogue of hypoxanthine. Additionally, this study extended the application of the sensor to detect pentoxifylline, an active pharmaceutical ingredient in pediatric medicines. These results underscore the taste sensor's value as an additional tool for early-stage assessment and prediction of bitterness in non-charged pharmaceuticals."

Journal • Pediatrics

A narrative review of theophylline: is there still a place for an old friend? (PubMed, J Thorac Dis) - "Moreover, we also aim to determine if there is a rationale for using low-dose theophylline due to its immunomodulatory and anti-inflammatory effect, or if the future of methylxanthines lies in newly synthesized derivates of theophylline such as bamifylline, or doxofylline...We searched the database since the year 2009 using the MeSH terms "theophylline", "aminophylline", and "methylxanthines" and we included original articles in the English language...There is considerable controversy associated with its use in current medicine, which can be attributed both to its narrow therapeutic range and its mentioned cardiotoxic effect. Herein, we summarize the current state-of-art of theophylline and its use in human medicine."

Journal • Review • Asthma • Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Correction: Effect of doxofylline on pulmonary inflammatory response and oxidative stress during mechanical ventilation in rats with COPD. (PubMed, BMC Pulm Med) - No abstract available

Journal • Preclinical • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Study on the Efficacy and Clinical Value of Aminophylline and Doxofylline in the Clinical Treatment of Chronic Obstructive Pulmonary Disease. (PubMed, Altern Ther Health Med) - "After treatment, the scores in various aspects of the quality of life of patients in both groups were significantly increased compared to those before treatment, and after comparing the scores of various quality of life between the two groups, it was found that the study group was higher than the control group (all P < .05). After the onset of COPD, doxofylline treatment can achieve better effects than aminophylline treatment."

Journal • Chronic Obstructive Pulmonary Disease • Cough • Immunology • Pulmonary Disease • Respiratory Diseases

Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease : A Randomized Crossover Study (clinicaltrials.gov) - P4 | N=20 | Not yet recruiting | Sponsor: Thammasat University

New P4 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Biochemical evaluation and ligand binding studies on glycerophosphodiester phosphodiesterase from Staphylococcus aureus using STD-NMR spectroscopy and molecular docking analysis. (PubMed, Bioorg Chem) - "In this study, competent E. coli BL21(DE3)pLysS expression cells were used to express the GDPD enzyme from vancomycin-resistant Staphylococcus aureus (VRSA), which was then purified using size exclusion and anion exchange chromatography...Out of 79 drugs, 13 drugs, including tenofovir (1), adenosine (2), clioquinol (11), bromazepam (12), lamotrigine (13), sulfadiazine (14), azathioprine (15), nicotine (16), sitagliptin PO4 (17), doxofylline (18), clindamycin phosphate (19), gentamycin sulphate (20), and ceftriaxone sodium (21) revealed varying degrees of inhibitory potential with IC50 values in the range of 400 ± 0.007-951 ± 0.016 µM...Exceptionally, tenofovir (1) was identified to be a better inhibitor with an IC50 value of 400 ± 0.007 µM, as compared to the standard EDTA (ethylenediaminetetraacetic acid) (IC50 = 470 ± 0.008 µM). Moreover, molecular docking studies have..."

Journal

Simultaneous and trace-level quantification of four benzene sulfonate potential genotoxic impurities in doxofylline active pharmaceutical ingredients and tablets using high-performance liquid chromatography with ultraviolet detection. (PubMed, Biomed Chromatogr) - "The accuracy of this method for the four PGIs ranged from 94.8% to 100.4%. The reverse-phase-HPLC-UV analytical method developed in this study is characterized by its speed and precision, making it suitable for the sensitive analysis of benzene sulfonate PGIs in doxofylline drug substances and tablets."

Journal

Doxofylline as a steroid-sparing treatment in Mexican children with asthma. (PubMed, J Asthma) - "Rescue medication use decreased significantly in patients receiving D + SDB during the first 4-week period. Our results suggest that doxofylline may be a steroid-sparing treatment in asthma, but longer-term, controlled studies are needed to confirm these observations."

Journal • Allergy • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Development of a new inhaled swellable microsphere system for the dual delivery of naringenin-loaded solid lipid nanoparticles and doxofylline for the treatment of asthma. (PubMed, Eur J Pharm Sci) - "In addition, in vivo studies conducted in mice, a murine model of asthma showed significant reductions in serum bicarbonate and eosinophil counts and improvement in respiratory flow rate, tidal volume, and bronchial wall lining compared with the asthmatic control group. Overall, this novel inhalable dual-delivery system may represent a good alternative for the effective treatment of asthma."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Bronchodilator effect of oral doxofylline and procaterol in asthma: a randomized crossover study (ERS 2023) - "Doxofylline and procaterol can improve asthma symptoms, though they are not able to enhance lung functions. These oral bronchodilators might be used as an add-on therapy for asthma treatment."

Clinical • Asthma • CNS Disorders • Immunology • Insomnia • Pain • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

Effects of doxofylline as an adjuvant on severe exacerbation and long-term prognosis for COPD with different clinical subtypes. (PubMed, Clin Respir J) - "As an adjuvant drug, doxofylline has a good therapeutic effect on patients with the neutrophilic and eosinophilic clinical subtypes of COPD. It can reduce the incidence of severe exacerbation, the use of glucocorticoids, and inflammatory reactions in the long term (when used for a minimum of 3 months)."

Clinical • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Studying the Mechanism of Interaction of Doxofylline with Human Lysozyme: A Biophysical and In Silico Approach. (PubMed, Molecules) - "All during the simulation time, hydrogen bonds were continuously present. The MM-PBSA binding energy for lysozyme and doxofylline binding was found to be -30.55 kcal mol."

Journal

Doxofylline ameliorates liver fibrosis by regulating the ferroptosis signaling pathway. (PubMed, Front Pharmacol) - "More importantly, ferroptosis inhibition using the specific inhibitor, deferoxamine (DFO) not only abolished DOX-induced ferroptosis, but also led to resistance to the anti-liver fibrosis effect of DOX in HSCs. In summary, our results showed an association between the protective effect of DOX against liver fibrosis and HSC ferroptosis. Thus, DOX may be a promising anti-hepatic fibrosis agent."

Journal • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • TGFB1

Doxofylline for Pediatric Asthma Steps 1-4. Pediatric Asthma: New Role for an Old Drug. (PubMed, Front Pediatr) - "Unlike theophylline, doxofylline does not require blood testing. It can be administered together with or as an alternative to a series of other drugs considered in additional therapy."

Journal • Review • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Doxofylline in acute exacerbation of chronic obstructive pulmonary disease. (PubMed, Rev Assoc Med Bras (1992)) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Effect of doxofylline on pulmonary inflammatory response and oxidative stress during mechanical ventilation in rats with COPD. (PubMed, BMC Pulm Med) - "Doxofylline was shown to improve ventilation and air exchange during mechanical ventilation in rats with COPD, reduce the inflammatory response and oxidative stress, and mitigate the degree of pulmonary tissue injury."

Journal • Preclinical • Anesthesia • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CXCL8 • IL10 • TNFA

Vmax Detection of Acupuncture-doxofylline as a Whole Probe of CYP1A in Vivo (clinicaltrials.gov) - P=N/A; N=10; Not yet recruiting; Sponsor: Shanghai Yueyang Integrated Medicine Hospital

New trial • Preclinical

Doxofylline Protects Gram-Negative Pathogens against Antibiotic-Mediated Killing. (PubMed, ACS Infect Dis) - "Collectively, our study indicates that doxofylline protects Gram-negative bacteria from antimicrobial lethality by regulating the AcrAB-TolC efflux pump in a TolC-dependent manner and suppressing antibiotic-induced ROS accumulation. These results suggest caution when using antibiotics alongside doxofylline in clinical treatment."

Journal • Infectious Disease • Respiratory Diseases

Efficacy and safety of combined doxofylline and salbutamol in treatment of acute exacerbation of chronic obstructive pulmonary disease. (PubMed, Rev Assoc Med Bras (1992)) - "In the treatment of acute exacerbation of chronic obstructive pulmonary disease, the combined use of doxofylline and salbutamol can quickly relieve the respiratory symptoms, mitigate the pulmonary dysfunction, and reduce the inflammatory response, thus promoting the outcome of patients."

Clinical • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CRP • CST3

Effect of Doxofylline on Reducing the Inflammatory Response in Mechanically Ventilated Rats with Chronic Obstructive Pulmonary Disease. (PubMed, Int J Chron Obstruct Pulmon Dis) - "Compared with group N, the W/D weight ratio and levels of TNF-α, JNK, and p-JNK in the pulmonary tissue decreased in group D (P < 0.05), while the levels of IL-10 increased (P < 0.05). Doxofylline might attenuate pulmonary inflammatory responses in mechanically ventilated rats with COPD, and the JNK/stress-activated protein kinase signaling pathway is involved in doxofylline's inhibition of inflammatory responses in the pulmonary tissue of rats with COPD."

Journal • Preclinical • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Oncology • Pulmonary Disease • Respiratory Diseases • IL10 • MAPK8 • TNFA

Effects of Doxofylline Combined with Ceftazidime on Clinical Efficacy, Drug Safety, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease Complicated with Infection. (PubMed, Med Sci Monit) - "CONCLUSIONS Doxofylline combined with ceftazidime effectively treated patients with COPD complicated with infection. These results provide a reference for clinical treatment."

Clinical • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • TNFA